Recent advanced lipid-based nanomedicines for overcoming cancer resistance

被引:4
|
作者
Dechbumroong, Piroonrat [1 ,2 ,3 ]
Hu, Runjing [1 ,2 ]
Keaswejjareansuk, Wisawat [3 ]
Namdee, Katawut [3 ]
Liang, Xing-Jie [1 ,2 ]
机构
[1] CAS Ctr Excellence Nanosci, Natl Ctr Nanosci & Technol China, CAS Key Lab Biomed Effects Nanomat & Nanosafety, 11 First North Rd, Beijing 100190, Peoples R China
[2] Univ Chinese Acad Sci, Sch Nanosci & Engn, Beijing 100049, Peoples R China
[3] Natl Sci & Technol Dev Agcy, Natl Nanotechnol Ctr NANOTEC, Khlong Nueng 12120, Pathum Thani, Thailand
基金
中国国家自然科学基金;
关键词
Cancer resistance; lipid -based nanomaterials; nanomedicines; drug delivery; CELL LUNG-CANCER; DRUG-RESISTANCE; BREAST-CANCER; MULTIDRUG-RESISTANCE; LIPOSOMES; NANOPARTICLES; DELIVERY; MECHANISMS; NANOMATERIALS; TRANSFERRIN;
D O I
10.20517/cdr.2024.19
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The increasing prevalence of cancer drug resistance not only critically limits the efficiency of traditional therapies but also causes relapses or recurrences of cancer. Consequently, there remains an urgent need to address the intricate landscape of drug resistance beyond traditional cancer therapies. Recently, nanotechnology has played an important role in the field of various drug delivery systems for the treatment of cancer, especially therapy-resistant cancer. Among advanced nanomedicine technologies, lipid-based nanomaterials have emerged as effective drug carriers for cancer treatment, significantly improving therapeutic effects. Due to their biocompatibility, simplicity of preparation, and potential for functionalization, lipid-based nanomaterials are considered powerful competitors for resistant cancer. In this review, an overview of lipid-based nanomaterials for addressing cancer resistance is discussed. We summarize the recent progress in overcoming drug resistance in cancer by these lipid-based nanomaterials, and highlight their potential in future applications to reverse cancer resistance.
引用
收藏
页码:2 / 24
页数:24
相关论文
共 50 条
  • [1] Microfluidic Manufacture of Lipid-Based Nanomedicines
    Osouli-Bostanabad, Karim
    Puliga, Sara
    Serrano, Dolores R.
    Bucchi, Andrea
    Halbert, Gavin
    Lalatsa, Aikaterini
    PHARMACEUTICS, 2022, 14 (09)
  • [2] Recent advances in lipid-based nanocarriers for advanced skin cancer therapy
    Ali, Mohd Shoab
    Almoyad, Mohammad Ali Abdullah
    Wahab, Shadma
    Sahebkar, Amirhossein
    Gorain, Bapi
    Kaur, Harleen
    Kesharwani, Prashant
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2025, 670
  • [3] Nanomedicines for Overcoming Cancer Drug Resistance
    Hu, Tingting
    Gong, Hanlin
    Xu, Jiayue
    Huang, Yuan
    Wu, Fengbo
    He, Zhiyao
    PHARMACEUTICS, 2022, 14 (08)
  • [4] Recent advances in functional lipid-based nanomedicines as drug carriers for organ-specific delivery
    Yun, Yeochan
    An, Jeongmin
    Kim, Hyun Joong
    Choi, Hye Kyu
    Cho, Hyeon-Yeol
    NANOSCALE, 2025, 17 (13) : 7617 - 7638
  • [5] Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments
    Leung, Ada W. Y.
    Kalra, Jessica
    Dos Santos, Nancy
    Bally, Marcel B.
    Anglesio, Michael S.
    NANOMEDICINE, 2014, 9 (03) : 501 - 522
  • [6] Characterization of lipid-based nanomedicines at the single-particle level
    Chen, Chaoxiang
    Chen, Chen
    Li, Yurou
    Gu, Ruilan
    Yan, Xiaomei
    FUNDAMENTAL RESEARCH, 2023, 3 (04): : 488 - 504
  • [7] Overcoming multidrug resistance with nanomedicines
    Ganoth, Assaf
    Merimi, Keren Cohen
    Peer, Dan
    EXPERT OPINION ON DRUG DELIVERY, 2015, 12 (02) : 223 - 238
  • [8] Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications
    Rajpoot, Kuldeep
    CURRENT CANCER DRUG TARGETS, 2020, 20 (04) : 271 - 287
  • [9] Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment
    Garcia-Pinel, Beatriz
    Porras-Alcala, Cristina
    Ortega-Rodriguez, Alicia
    Sarabia, Francisco
    Prados, Jose
    Melguizo, Consolacion
    Lopez-Romero, Juan M.
    NANOMATERIALS, 2019, 9 (04)
  • [10] Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis
    Smith, Lindsay
    Serrano, Dolores R.
    Mauger, Marion
    Bolas-Fernandez, Francisco
    Auxiliadora Dea-Ayuela, Maria
    Lalatsa, Aikaterini
    MOLECULAR PHARMACEUTICS, 2018, 15 (07) : 2570 - 2583